Quantifying ER Expression: The Key to Personalizing Treatment in HER2-Negative ER-positive Breast Cancer
In this MEDtalk, Qiao Yang, a PhD student in Professor Johan Hartman’s research group at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, presents the clinical significance of estrogen receptor expression subgroups in patients with HER2-negative breast cancer based on real-world data.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
